Medical Pharmacology: Chapter 34 — Anti-Cancer Drugs Part II -- Module 4 — Immune Checkpoint Inhibitors, Hormonal Oncology, and CAR-T Cell Therapy: Core Concepts

Chapter 34 — Anti-Cancer Drugs Part II — Module 4 — Immune Checkpoint Inhibitors, Hormonal Oncology, and CAR-T Cell Therapy: Core Concepts

1. Immune checkpoint inhibitors are a class of anti-cancer drugs that act on the immune system rather than directly on tumor cells. Under normal conditions, immune checkpoints (molecules such as CTLA-4 and PD-1 on the surface of T cells) function as "brakes" that prevent T cells from attacking the body's own tissues. What is the basic therapeutic strategy of a checkpoint inhibitor?

A) It directly delivers a cytotoxic drug into tumor cells while sparing normal cells.
B) It blocks the inhibitory checkpoint signal, releasing the brake on T cells so they can attack the tumor.
C) It replaces the patient's T cells with genetically engineered donor T cells.
D) It stimulates the bone marrow to produce a larger number of red blood cells.
E) It inhibits an intracellular enzyme that tumors need for DNA replication.

ANSWER: B

Rationale:

Immune checkpoints are normally protective brakes: signaling through CTLA-4 and PD-1 dampens T-cell activation so the immune system does not attack healthy tissue. Tumors exploit this by engaging these checkpoints to evade immune attack. A checkpoint inhibitor is an antibody that blocks the checkpoint signal, removing the brake and allowing T cells to recognize and kill tumor cells. This explains why their characteristic toxicities are autoimmune in nature — the same released brake that lets T cells attack the tumor can also let them attack normal tissue.

Option A: Option A describes an antibody-drug conjugate, a different class that uses an antibody to deliver a cytotoxic payload to tumor cells.
Option C: Option C describes CAR-T cell therapy, which engineers a patient's own (not donor) T cells; it is not a checkpoint inhibitor.
Option D: Option D describes an erythropoiesis-stimulating agent, which is supportive care unrelated to checkpoint biology.
Option E: Option E describes a conventional cytotoxic or targeted small-molecule mechanism, not the immune-release mechanism of checkpoint blockade.

2. The two main families of checkpoint inhibitors target either CTLA-4 or the PD-1/PD-L1 axis. CTLA-4 (a checkpoint expressed on T cells) and PD-1 (a separate checkpoint also on T cells) act at different points in the immune response. Which statement correctly distinguishes where these two checkpoints act?

A) CTLA-4 and PD-1 act at exactly the same step, so blocking either one produces identical effects.
B) CTLA-4 acts only inside tumor cells, while PD-1 acts only on circulating red blood cells.
C) CTLA-4 acts early during T-cell priming in lymph nodes, while PD-1/PD-L1 acts later when T cells encounter tumor tissue in the periphery.
D) PD-1 acts early during priming in lymph nodes, while CTLA-4 acts only after the tumor has metastasized.
E) Both checkpoints act exclusively on B cells rather than T cells.

ANSWER: C

Rationale:

CTLA-4 functions early, during the priming phase when T cells are first activated by antigen-presenting cells in lymph nodes; blocking it (ipilimumab) broadens the pool of activated T cells. PD-1/PD-L1 functions later, in the effector phase, when activated T cells reach peripheral tissue and the tumor; blocking it (nivolumab, pembrolizumab) restores T-cell activity at the tumor site. This early-versus-late distinction explains why combination CTLA-4 plus PD-1 blockade is more potent but also more toxic than either agent alone.

Option A: Option A is incorrect because the two checkpoints act at distinct phases, and blockade of each produces different efficacy and toxicity profiles.
Option B: Option B is incorrect because both are T-cell checkpoints, not intracellular tumor molecules or red-cell molecules.
Option D: Option D inverts the correct timing — it is CTLA-4, not PD-1, that acts early in lymph node priming.
Option E: Option E is incorrect because these are T-cell checkpoints, not B-cell molecules.

3. A defining feature of immune checkpoint inhibitors is their characteristic pattern of side effects, called immune-related adverse events (irAEs). Based on how these drugs work, what kind of toxicity should a clinician anticipate?

A) Autoimmune-type inflammation of normal organs, such as colitis, hepatitis, pneumonitis, and endocrine gland dysfunction.
B) Severe bone marrow suppression with predictable neutropenia 10 to 14 days after every dose.
C) Irreversible kidney failure caused by direct tubular toxicity from a heavy-metal component.
D) Hair loss and mouth sores identical to those seen with classic cytotoxic chemotherapy.
E) A complete absence of any side effects, because the drugs act only on tumor cells.

ANSWER: A

Rationale:

Because checkpoint inhibitors work by releasing the brakes on T cells, the same unleashed immune activity can turn against normal tissues, producing autoimmune-style inflammation. These immune-related adverse events can affect almost any organ — the colon (colitis), liver (hepatitis), lungs (pneumonitis), and endocrine glands (thyroid, pituitary, adrenal) are among the most clinically important. Recognizing that the toxicity is autoimmune in nature is the key concept, because management centers on immunosuppression with corticosteroids rather than on the supportive measures used for cytotoxic chemotherapy.

Option B: Option B describes the predictable myelosuppression of cytotoxic chemotherapy, not the immune-mediated toxicity of checkpoint blockade.
Option C: Option C describes a heavy-metal nephrotoxicity pattern (as with cisplatin), unrelated to checkpoint inhibitors.
Option D: Option D describes classic cytotoxic chemotherapy effects (alopecia, mucositis), which are not the signature of checkpoint inhibitors.
Option E: Option E is incorrect because these drugs have a well-defined and sometimes serious toxicity profile precisely because they act on the immune system, not solely on tumor cells.

4. A patient receiving a PD-1 inhibitor develops moderate immune-related colitis (inflammation of the colon causing several extra loose stools per day). After infection has been excluded, what is the cornerstone of initial treatment for a significant immune-related adverse event like this?

A) Increasing the dose of the checkpoint inhibitor to overwhelm the inflammation.
B) Starting a long-acting opioid as the primary therapy for the inflammation.
C) Beginning broad-spectrum antibiotics as the definitive treatment for the colitis.
D) Starting systemic corticosteroids (for example, prednisone) to suppress the overactive immune response.
E) Administering an erythropoiesis-stimulating agent to raise the red blood cell count.

ANSWER: D

Rationale:

Immune-related adverse events are driven by an overactive immune response, so the logical and guideline-based cornerstone of treatment for a significant irAE is systemic corticosteroid therapy (commonly prednisone roughly 1 mg/kg/day for moderate-to-severe events) to dampen that response. The conceptual link is direct: the drug works by releasing an immune brake, so the antidote to excessive immune activity is to re-impose suppression with steroids. Underdosing steroids or tapering them too quickly is a common cause of irAE relapse.

Option A: Option A is incorrect and dangerous because raising the checkpoint inhibitor dose would intensify, not calm, the immune attack.
Option B: Option B is incorrect because an opioid might reduce stool frequency symptomatically but does nothing to treat the underlying immune inflammation.
Option C: Option C is incorrect because antibiotics treat infection, which must be excluded but is not the cause of immune colitis.
Option E: Option E is incorrect because raising the red cell count is unrelated to treating immune-mediated inflammation.

5. Hormonal therapy for prostate cancer often begins with a GnRH agonist (a drug such as leuprolide that continuously stimulates the pituitary gland's receptor for gonadotropin-releasing hormone). When such a drug is first started, what initial hormonal effect occurs before testosterone levels eventually fall?

A) An immediate and permanent rise in estrogen with no effect on testosterone.
B) An instant drop in testosterone to castrate levels within the first hour.
C) A complete shutdown of the adrenal glands within minutes of the first dose.
D) No hormonal change at all for the first several months of therapy.
E) A transient surge ("flare") in testosterone before the pituitary downregulates and testosterone falls.

ANSWER: E

Rationale:

Continuous (rather than pulsatile) stimulation of the pituitary GnRH receptor first triggers a surge of luteinizing hormone, which transiently raises testosterone — the "flare" — over the first one to two weeks. Only after the receptor downregulates does testosterone fall to castrate levels. This concept matters clinically because the flare can temporarily worsen disease (for example, precipitating spinal cord compression in a patient with vertebral metastases), which is why a short course of an antiandrogen is given to cover the flare.

Option A: Option A is incorrect because the primary effect is on testosterone via luteinizing hormone, not an isolated permanent estrogen rise.
Option B: Option B inverts the time course — testosterone initially rises, and the fall to castrate levels takes weeks, not one hour.
Option C: Option C is incorrect because GnRH agonists act on the pituitary-gonadal axis, not by shutting down the adrenal glands.
Option D: Option D is incorrect because a measurable hormonal change (the flare) begins almost immediately.

6. Abiraterone treats prostate cancer by blocking CYP17A1, an enzyme required to make androgens (male hormones) in the adrenal glands, testes, and tumor tissue. Blocking this same enzyme in the adrenal cortex also reduces cortisol, which triggers a compensatory rise in pituitary signaling and a buildup of mineralocorticoid hormones (which raise blood pressure and lower potassium). Why is abiraterone always given together with low-dose prednisone?

A) Prednisone replaces the cortisol that is no longer made and suppresses the pituitary drive, preventing the mineralocorticoid excess that would otherwise cause hypertension and low potassium.
B) Prednisone is given to directly kill prostate cancer cells through a cytotoxic mechanism.
C) Prednisone is added to increase abiraterone absorption from the gut.
D) Prednisone prevents the hair loss that abiraterone otherwise causes.
E) Prednisone is given to raise testosterone back to normal during therapy.

ANSWER: A

Rationale:

By inhibiting CYP17A1, abiraterone lowers cortisol synthesis; the pituitary responds by increasing adrenocorticotropic hormone, which drives accumulation of mineralocorticoid precursors upstream of the blocked enzyme. These mineralocorticoids cause hypertension, hypokalemia, and fluid retention. Concurrent low-dose prednisone replaces cortisol and suppresses the pituitary drive, preventing this syndrome — which is exactly why the combination is mandatory.

Option B: Option B is incorrect because the prednisone here is physiologic replacement and pituitary suppression, not a cytotoxic anti-cancer treatment.
Option C: Option C is incorrect because prednisone does not enhance abiraterone absorption; in fact abiraterone has its own absorption rule (taken on an empty stomach).
Option D: Option D is incorrect because preventing hair loss is not the reason for co-administration.
Option E: Option E is incorrect because the therapeutic goal is to lower androgens, not to restore testosterone.

7. Tamoxifen is used to treat hormone-receptor-positive breast cancer. It is a prodrug, meaning it must be converted by a liver enzyme (CYP2D6) into its active form, endoxifen, to work fully. A patient on tamoxifen asks her physician about taking paroxetine (a strong CYP2D6 inhibitor) for hot flashes. Why is this combination generally avoided?

A) Paroxetine speeds up tamoxifen breakdown, causing toxic levels to accumulate.
B) Paroxetine and tamoxifen combine to cause severe immediate bone marrow failure.
C) Paroxetine blocks CYP2D6, reducing conversion of tamoxifen to active endoxifen and potentially lowering tamoxifen's effectiveness.
D) Paroxetine prevents tamoxifen from being absorbed in the stomach entirely.
E) Paroxetine converts tamoxifen into a pure estrogen agonist that stimulates the tumor.

ANSWER: C

Rationale:

Tamoxifen depends on CYP2D6 to generate its active metabolite endoxifen. A strong CYP2D6 inhibitor such as paroxetine (or fluoxetine) reduces endoxifen formation, which can diminish tamoxifen's anti-tumor benefit. The practical consequence is to choose a different agent for hot flashes — venlafaxine, desvenlafaxine, gabapentin, or clonidine — that does not significantly inhibit CYP2D6.

Option A: Option A is incorrect because inhibiting CYP2D6 reduces formation of the active metabolite rather than causing toxic parent-drug accumulation that drives toxicity; the clinical concern is lost efficacy.
Option B: Option B is incorrect because this combination does not cause acute bone marrow failure.
Option D: Option D is incorrect because the issue is impaired metabolic activation, not blocked gastrointestinal absorption.
Option E: Option E is incorrect because paroxetine does not chemically transform tamoxifen into an estrogen agonist.

8. Aromatase inhibitors (drugs such as letrozole and anastrozole) treat hormone-receptor-positive breast cancer by blocking aromatase, the enzyme that converts androgens into estrogen in tissues outside the ovary (fat, adrenal, and breast tissue). Why are these drugs effective only in postmenopausal women (or premenopausal women whose ovaries have been suppressed)?

A) Aromatase inhibitors only work when the ovaries are actively producing large amounts of estrogen.
B) In postmenopausal women, ovarian estrogen production has ceased, so blocking the extragonadal (outside-the-ovary) source removes the dominant remaining estrogen supply.
C) Aromatase inhibitors directly destroy the ovaries, so they are reserved for women who still have functioning ovaries.
D) The drugs require high circulating testosterone, which only premenopausal women have.
E) Aromatase inhibitors work in any patient regardless of menopausal or ovarian status.

ANSWER: B

Rationale:

After menopause, the ovaries no longer produce estrogen, and the main remaining source becomes the peripheral conversion of androgens to estrogen by aromatase in fat, adrenal, and breast tissue. Blocking aromatase therefore removes the dominant estrogen supply in postmenopausal women. In a premenopausal woman, the ovaries still make large amounts of estrogen that aromatase inhibition cannot control (and the resulting feedback can even increase ovarian stimulation), so the drugs are used only with ovarian suppression.

Option A: Option A is incorrect because it inverts the truth: active ovarian production is precisely the situation where these drugs fail to control estrogen.
Option C: Option C is incorrect because aromatase inhibitors block an enzyme; they do not physically destroy the ovaries.
Option D: Option D is incorrect because the mechanism depends on blocking estrogen synthesis, not on requiring high testosterone.
Option E: Option E is incorrect because menopausal/ovarian status is exactly what determines whether these drugs work.

9. CAR-T cell therapy (chimeric antigen receptor T-cell therapy) is a form of cellular immunotherapy used for certain blood cancers. In simple terms, what does this treatment involve?

A) Injecting a small-molecule drug that blocks an enzyme tumors need to divide.
B) Giving an antibody that delivers a radioactive particle directly to bone.
C) Transplanting an entire donor immune system to replace the patient's own.
D) Administering a daily oral pill that slowly starves tumor cells of hormones.
E) Collecting the patient's own T cells, genetically engineering them to recognize a tumor surface antigen, then expanding and reinfusing them.

ANSWER: E

Rationale:

CAR-T therapy collects a patient's own T cells by leukapheresis, genetically engineers them to express a chimeric antigen receptor that recognizes a specific tumor surface antigen (such as CD19 on B-cell cancers), expands them in culture, and reinfuses them so they can find and kill the tumor. The key concept is that the living cells are the therapy, and they are derived from the patient, not a donor.

Option A: Option A describes a small-molecule targeted drug, not a cell therapy.
Option B: Option B describes a radiopharmaceutical, a different modality.
Option C: Option C is incorrect because CAR-T does not transplant a whole donor immune system — it re-engineers the patient's own T cells.
Option D: Option D describes oral hormonal therapy, which is unrelated to engineered cell therapy.

10. A common and potentially serious complication after CAR-T infusion is cytokine release syndrome (CRS), a systemic inflammatory reaction driven largely by the cytokine interleukin-6 (IL-6). A patient develops fever and fluid-responsive low blood pressure a few days after CAR-T infusion. Which treatment specifically targets the main driver of CRS?

A) High-dose intravenous antibiotics directed at gram-negative bacteria.
B) An erythropoiesis-stimulating agent to correct the low blood pressure.
C) A loop diuretic to remove the excess cytokines through the urine.
D) Tocilizumab, an antibody that blocks the IL-6 receptor.
E) A GnRH agonist to suppress the inflammatory hormone surge.

ANSWER: D

Rationale:

CRS is driven substantially by IL-6, so the targeted treatment is tocilizumab, a monoclonal antibody that blocks the IL-6 receptor; corticosteroids are added for higher-grade or refractory CRS. Connecting the mechanism (IL-6-driven inflammation) to the therapy (IL-6 receptor blockade) is the core concept.

Option A: Option A is incorrect because, although infection must always be considered with fever, CRS itself is a cytokine-driven process, not a bacterial infection, and antibiotics do not treat it.
Option B: Option B is incorrect because raising the red cell count does not address cytokine-mediated hypotension.
Option C: Option C is incorrect because cytokines are not cleared meaningfully by diuresis, and a diuretic could worsen the hypotension.
Option E: Option E is incorrect because GnRH agonists act on the pituitary-gonadal axis and have no role in CRS.

11. ICANS (immune effector cell-associated neurotoxicity syndrome) is a neurological complication of CAR-T therapy that causes confusion, difficulty speaking, and in severe cases seizures. It is mechanistically distinct from cytokine release syndrome. Which statement correctly describes the treatment principle for ICANS?

A) Corticosteroids (such as dexamethasone) are the mainstay; tocilizumab is not effective for ICANS and may even worsen it.
B) Tocilizumab alone reliably reverses ICANS because IL-6 receptor blockade clears neurotoxicity.
C) ICANS requires no treatment because it is always permanent and untreatable.
D) The first step is to increase the CAR-T cell dose to outcompete the neurotoxicity.
E) ICANS is treated exclusively with broad-spectrum antibiotics directed at the brain.

ANSWER: A

Rationale:

ICANS responds to corticosteroids (dexamethasone is standard), which cross into the central nervous system and suppress the inflammatory injury. Unlike CRS, ICANS is not effectively treated by tocilizumab; blocking the IL-6 receptor peripherally can raise free IL-6 that crosses into the brain and may worsen neurotoxicity. The high-yield concept is the contrast: CRS responds to tocilizumab first, but ICANS is treated with steroids.

Option B: Option B is incorrect precisely because tocilizumab does not reliably reverse ICANS and may aggravate it.
Option C: Option C is incorrect because ICANS is treatable and is generally reversible in most cases with prompt steroids.
Option D: Option D is incorrect and dangerous because raising the CAR-T dose would intensify the immune-mediated injury.
Option E: Option E is incorrect because ICANS is an inflammatory/neurotoxic process, not a bacterial central nervous system infection.

12. Enzalutamide is an oral drug for prostate cancer that blocks the androgen receptor. It is also a strong inducer of CYP3A4 (a major liver enzyme that breaks down many drugs). A patient stabilized on warfarin is started on enzalutamide. Based on the enzyme-induction concept, what should the clinician anticipate?

A) Warfarin levels will rise sharply, requiring an immediate dose increase to avoid clotting.
B) Enzalutamide has no possible effect on other medications because it acts only on the prostate.
C) Warfarin will be converted into an active anti-cancer agent by enzalutamide.
D) Enzalutamide will block warfarin absorption from the gut entirely.
E) Warfarin levels and effect may fall because faster enzyme-driven breakdown lowers its plasma concentration.

ANSWER: E

Rationale:

Enzyme induction means the liver makes more of the metabolizing enzyme, so substrates of that enzyme are cleared faster and their plasma levels fall. As a strong CYP3A4 (and CYP2C9/CYP2C19) inducer, enzalutamide can lower concentrations of many co-administered drugs, including warfarin; closer monitoring (for example, the international normalized ratio for warfarin) and dose adjustment are needed. The concept to carry forward is that induction reduces, rather than raises, substrate levels.

Option A: Option A is incorrect because it is the opposite of induction: it describes inhibition causing accumulation, which is not what enzalutamide does.
Option B: Option B is incorrect because a strong enzyme inducer has broad effects on many co-administered drugs.
Option C: Option C is incorrect because enzalutamide does not chemically transform warfarin into an anti-cancer drug.
Option D: Option D is incorrect because the mechanism is accelerated metabolism, not blocked gastrointestinal absorption.

13. A patient on a PD-1 inhibitor develops a low thyroid-stimulating hormone (TSH) with an elevated thyroid hormone level and a heart rate of 110 beats per minute — a picture of hyperthyroidism caused by immune-mediated thyroiditis (inflammation of the thyroid). Understanding the natural course of this immune-related event, what is the appropriate initial management?

A) Start lifelong high-dose antithyroid drug therapy immediately, as the hyperthyroidism is permanent.
B) Permanently stop all future thyroid monitoring once the hyperthyroid phase is recognized.
C) Treat symptoms with a beta-blocker, recognizing the hyperthyroid phase is usually transient and often transitions to hypothyroidism.
D) Begin levothyroxine immediately to treat the elevated thyroid hormone level.
E) Surgically remove the thyroid gland as the first-line treatment.

ANSWER: C

Rationale:

Immune-mediated thyroiditis from a checkpoint inhibitor typically begins with a transient hyperthyroid phase, as preformed thyroid hormone stored in the gland is released by inflammation. Because this phase is self-limited, management is symptomatic — a beta-blocker controls palpitations and tachycardia — and the patient is monitored, because the gland commonly burns out and becomes hypothyroid within weeks. The concept connects the transient pathophysiology to restrained, symptom-directed treatment.

Option A: Option A is incorrect because the hyperthyroidism is transient, not permanent, so committing to lifelong antithyroid therapy is inappropriate.
Option B: Option B is incorrect because ongoing thyroid monitoring is essential precisely to catch the expected transition to hypothyroidism.
Option D: Option D is incorrect because levothyroxine treats hypothyroidism and would worsen the current hyperthyroid phase; it is started later if the patient becomes hypothyroid.
Option E: Option E is incorrect because thyroidectomy is not a treatment for transient immune thyroiditis.

14. Somatostatin analogs (drugs such as octreotide and lanreotide) are used for neuroendocrine tumors — tumors that often overproduce hormones causing symptoms like flushing and diarrhea. These drugs mimic the body's hormone somatostatin, which suppresses secretion. With long-term use, which characteristic adverse effect should be monitored for?

A) Acute hair loss within days of the first injection.
B) Biliary sludge and gallstones, because reduced gallbladder contraction promotes stone formation.
C) Immediate severe bone marrow suppression after each dose.
D) Permanent red discoloration of the urine that signals kidney failure.
E) A rapid rise in testosterone causing a tumor flare.

ANSWER: B

Rationale:

Somatostatin analogs suppress secretion of multiple hormones and also reduce gallbladder motility; over time, decreased gallbladder contraction promotes biliary sludge and gallstone formation, so periodic abdominal ultrasound monitoring is recommended. The concept links the broad secretion-suppressing action to a predictable gallbladder consequence.

Option A: Option A is incorrect because acute alopecia is not a characteristic effect of somatostatin analogs.
Option C: Option C is incorrect because these drugs do not cause acute marrow suppression like cytotoxic chemotherapy.
Option D: Option D is incorrect because red urine and kidney failure are not features of somatostatin analog therapy.
Option E: Option E is incorrect because the testosterone-flare phenomenon belongs to GnRH agonists in prostate cancer, not to somatostatin analogs.

15. Before starting a checkpoint inhibitor, oncologists often test the tumor for predictive biomarkers — measurable tumor features that help estimate how likely the drug is to work. Which of the following is a recognized predictive biomarker of response to checkpoint inhibitor therapy?

A) A low resting heart rate measured before the first infusion.
B) The patient's ABO blood group.
C) The serum sodium concentration at baseline.
D) High PD-L1 expression, high tumor mutational burden, or microsatellite instability-high/mismatch-repair-deficient status.
E) The patient's height and weight at diagnosis.

ANSWER: D

Rationale:

Tumor features that predict a stronger response to checkpoint blockade include high PD-L1 expression (more of the ligand the drug targets), high tumor mutational burden (more neoantigens for T cells to recognize), and microsatellite instability-high or mismatch-repair-deficient status (a defect that generates many mutations). These biomarkers connect tumor biology to the likelihood of benefit.

Option A: Option A is incorrect because heart rate is a vital sign with no predictive value for immunotherapy response.
Option B: Option B is incorrect because blood group does not predict checkpoint inhibitor efficacy.
Option C: Option C is incorrect because serum sodium is a general metabolic value unrelated to immunotherapy response prediction.
Option E: Option E is incorrect because height and weight inform dosing in some regimens but do not predict response to checkpoint blockade.

16. Earlier questions established that CTLA-4 blockade acts early during T-cell priming and PD-1/PD-L1 blockade acts later at the tumor site, and that checkpoint inhibitor toxicity is autoimmune in nature. Applying both ideas, what would you predict about combining a CTLA-4 inhibitor with a PD-1 inhibitor compared with using either drug alone?

A) The combination is generally more effective but also produces more frequent and more severe immune-related adverse events.
B) The combination is less effective than either single agent because the two drugs cancel each other out.
C) The combination eliminates immune-related adverse events entirely.
D) The combination converts the therapy into a conventional cytotoxic chemotherapy regimen.
E) The combination only works if the patient has no immune system at all.

ANSWER: A

Rationale:

Releasing two different brakes at two different stages of the immune response (priming and effector phases) produces more robust T-cell activation, which tends to improve anti-tumor efficacy. Because the toxicity is autoimmune and driven by that same released immune activity, more activation also means more frequent and more severe immune-related adverse events — the predictable trade-off of dual blockade. This bridges the early/late concept with the autoimmune-toxicity concept.

Option B: Option B is incorrect because the drugs act at complementary, not opposing, steps, so they do not cancel out.
Option C: Option C is incorrect because more immune activation increases, rather than eliminates, immune-related adverse events.
Option D: Option D is incorrect because the combination remains immunotherapy; it does not become cytotoxic chemotherapy.
Option E: Option E is incorrect because the therapy depends on a functioning T-cell response, not on its absence.

17. Recall the testosterone "flare" that occurs when a GnRH agonist is first started. A man with metastatic prostate cancer involving the vertebrae (spine) is about to begin leuprolide. Applying the flare concept to this specific patient, what is the appropriate protective step?

A) Give the leuprolide alone and simply observe, since the flare poses no risk in this patient.
B) Start lifelong high-dose corticosteroids before the leuprolide.
C) Begin an aromatase inhibitor to block the testosterone surge.
D) Withhold all cancer treatment until the metastases resolve on their own.
E) Co-administer a short course of an antiandrogen (such as bicalutamide) starting before and during leuprolide initiation to blunt the flare.

ANSWER: E

Rationale:

The early testosterone surge from a GnRH agonist can transiently stimulate tumor growth, and in a patient with vertebral metastases this raises the danger of spinal cord compression. The protective step is to give a short course of an antiandrogen (for example, bicalutamide) beginning before and continuing during leuprolide initiation, so the flare's effect on the tumor is blocked at the receptor. This bridges the flare mechanism to a specific high-risk clinical scenario.

Option A: Option A is incorrect and unsafe because the flare is precisely dangerous in a patient with spinal metastases.
Option B: Option B is incorrect because corticosteroids do not block the androgen receptor and are not the standard flare-protection strategy.
Option C: Option C is incorrect because aromatase inhibitors are used in breast cancer and do not address the testosterone flare in prostate cancer.
Option D: Option D is incorrect because withholding treatment leaves the cancer untreated and the patient at risk.

18. Two CAR-T complications were established earlier: cytokine release syndrome (CRS), driven by IL-6 and treated first with tocilizumab, and ICANS, a neurotoxicity treated with corticosteroids rather than tocilizumab. Four days after CAR-T infusion, a patient develops high fever and low blood pressure that improves with intravenous fluids, but has a normal neurological examination. Using the distinction between these two syndromes, what is the appropriate targeted treatment?

A) Dexamethasone alone, because the picture is purely neurotoxicity.
B) No treatment, because fever after CAR-T never requires intervention.
C) Tocilizumab, because fever with hypotension and a normal neurological exam fits CRS rather than ICANS.
D) An antiandrogen, to blunt the inflammatory surge.
E) Levothyroxine, to correct the presumed thyroid cause.

ANSWER: C

Rationale:

Fever with fluid-responsive hypotension and a normal neurological examination is the picture of CRS, the IL-6-driven syndrome, so the targeted treatment is tocilizumab (with steroids reserved for higher-grade or refractory disease). Because there are no neurological findings, this is not ICANS, where steroids — not tocilizumab — would be used. This bridges the CRS-versus-ICANS distinction to a specific bedside presentation.

Option A: Option A is incorrect because there are no neurological findings to indicate ICANS, so steroid-first treatment for neurotoxicity does not fit.
Option B: Option B is incorrect because CRS can be serious and this presentation requires treatment (after infection is considered).
Option D: Option D is incorrect because antiandrogens treat prostate cancer and have no role in CRS.
Option E: Option E is incorrect because there is no evidence of thyroid dysfunction here, and levothyroxine does not treat CRS.

19. Earlier you learned that abiraterone blocks androgen synthesis and must be paired with prednisone. Abiraterone also has an important administration rule: taking the standard formulation with food (especially a high-fat meal) markedly increases the amount absorbed. Applying this property, what instruction should a patient receive about taking standard abiraterone?

A) Take it with the largest, highest-fat meal of the day to guarantee absorption.
B) Take it on an empty stomach, because food can substantially and unpredictably increase drug exposure and toxicity.
C) Take it only when symptoms of cancer flare appear, rather than on a schedule.
D) Crush it into a hot beverage to improve its effect.
E) Take it together with a strong CYP3A4 inducer to boost its levels.

ANSWER: B

Rationale:

The standard abiraterone formulation shows greatly increased absorption when taken with food — a high-fat meal can raise exposure several-fold — which makes dosing unpredictable and increases toxicity risk. The instruction is therefore to take it on an empty stomach (a consistent fasting state) so exposure stays predictable. This bridges a pharmacokinetic property to a concrete patient instruction.

Option A: Option A is incorrect because it is the opposite of the correct instruction and would produce excessive, unpredictable drug levels.
Option C: Option C is incorrect because abiraterone is taken on a fixed daily schedule, not as needed for symptoms.
Option D: Option D is incorrect because crushing into a hot drink is not an approved or sensible administration method and does not address the food effect.
Option E: Option E is incorrect because adding a strong enzyme inducer would tend to lower, not usefully raise, drug levels and is not an administration instruction.

20. Among the androgen-receptor inhibitors, enzalutamide can lower the seizure threshold and is avoided in patients with a seizure history, whereas darolutamide is structurally designed to enter the brain less and does not cause seizures at therapeutic doses. A man with prostate cancer and a documented prior seizure disorder needs an androgen-receptor inhibitor. Applying these distinctions, which agent is the better choice and why?

A) Enzalutamide, because its strong central nervous system penetration is protective against seizures.
B) Either agent equally, because androgen-receptor inhibitors have no relationship to seizure risk.
C) Enzalutamide, because seizure history increases its anti-tumor effect.
D) Darolutamide, because its reduced central nervous system penetration avoids the seizure risk seen with enzalutamide.
E) Neither agent can ever be used in a patient who has had a seizure.

ANSWER: D

Rationale:

Darolutamide's structure limits its entry into the central nervous system, so it does not lower the seizure threshold the way enzalutamide can; this makes it the preferable androgen-receptor inhibitor for a patient with a seizure history. The bridge here is matching a drug's central nervous system penetration to a patient-specific safety concern.

Option A: Option A is incorrect because greater central nervous system penetration is what raises, not lowers, seizure risk.
Option B: Option B is incorrect because these agents differ meaningfully in central nervous system effects and seizure risk.
Option C: Option C is incorrect because seizure history is a safety concern, not a driver of anti-tumor efficacy.
Option E: Option E is incorrect because an appropriate agent (darolutamide) can be used; a seizure history does not preclude all androgen-receptor inhibitors.

21. Checkpoint inhibitors can damage the pituitary or adrenal glands, leading to adrenal insufficiency (inadequate cortisol production). A patient on a checkpoint inhibitor presents with low blood pressure, vomiting, low sodium, and high potassium — a picture consistent with adrenal crisis. Building on the principle that immune-related adverse events are managed by understanding the affected organ, what is the correct immediate action?

A) Give intravenous hydrocortisone (stress-dose corticosteroid) immediately, without waiting for confirmatory test results.
B) Withhold all steroids until a full endocrine workup returns over the next several days.
C) Start a beta-blocker as the primary treatment for the low blood pressure.
D) Increase the checkpoint inhibitor dose to restore adrenal function.
E) Administer levothyroxine as the definitive treatment for adrenal crisis.

ANSWER: A

Rationale:

Adrenal crisis is life-threatening, and the affected organ (the adrenal gland) is failing to produce cortisol; the immediate, life-saving action is to give stress-dose intravenous hydrocortisone without waiting for confirmatory testing. This applies the irAE principle — treat based on the failing organ — to an emergency where delay can be fatal.

Option B: Option B is incorrect and dangerous because withholding steroids during a suspected adrenal crisis to await testing can be fatal.
Option C: Option C is incorrect because a beta-blocker does not replace the missing cortisol and would not treat the underlying crisis (and could worsen hypotension).
Option D: Option D is incorrect because raising the checkpoint inhibitor dose would not restore adrenal function and could worsen immune-mediated gland damage.
Option E: Option E is incorrect because levothyroxine treats hypothyroidism, not adrenal insufficiency, and giving it alone in adrenal crisis can precipitate further deterioration.

22. For immune-related colitis that does not respond to steroids, infliximab (an anti-TNF antibody) is a recognized steroid-sparing option. For immune-related hepatitis (liver inflammation), however, infliximab is generally avoided. A patient on a checkpoint inhibitor develops steroid-refractory immune hepatitis. Applying the organ-specific reasoning behind irAE management, what is the appropriate next step?

A) Switch to infliximab, since it is the preferred steroid-sparing agent for every immune-related adverse event.
B) Stop all immunosuppression and simply continue the checkpoint inhibitor.
C) Give a GnRH agonist to reduce hepatic inflammation.
D) Begin an aromatase inhibitor as the steroid-sparing liver therapy.
E) Add mycophenolate mofetil as the steroid-sparing agent, avoiding infliximab because of its own potential for liver toxicity.

ANSWER: E

Rationale:

In steroid-refractory immune hepatitis, the steroid-sparing agent of choice is mycophenolate mofetil, and infliximab is avoided because it carries its own risk of liver toxicity. This contrasts with immune colitis, where infliximab is appropriate — illustrating that the right steroid-sparing agent depends on which organ is affected.

Option A: Option A is incorrect precisely because infliximab is not appropriate for every irAE; its hepatotoxicity makes it a poor choice for immune hepatitis.
Option B: Option B is incorrect because steroid-refractory hepatitis requires escalation of immunosuppression, not abandonment of treatment, and the checkpoint inhibitor is typically held.
Option C: Option C is incorrect because GnRH agonists act on the pituitary-gonadal axis and have no role in treating hepatitis.
Option D: Option D is incorrect because aromatase inhibitors treat breast cancer and do not serve as steroid-sparing immunosuppression for the liver.